Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) — Duc Binh Phan (2023) | RDL Network
Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)
Article 2023 en
Authors
DP
Duc Binh Phan
AB
Anthony Bewley
CS
Catherine Smith
Abstract
1 min read
The uptake of biosimilars increased over time and varied considerably across the UK and Ireland; adalimumab had the highest biosimilar uptake rate compared with that of other TNFi drugs.
Oras Alabas, K.J. Mason, Zenas Z N Yiu, Catherine Smith, Richard B. Warren, Christopher Em Griffiths, Juliet N. Barker, Simon Morrison, Anthony Bewley, Ian Evans, Christopher Griffiths, Shehnaz Ahmed, Brian Kirby, Elise Kleyn, Philip Laws, Philip Hampton, Oras Alabas, Kathleen McElhone, Zenas Z N Yiu, Teena Mackenzie, Tess McPherson, Ruth Murphy, Anthony D. Ormerod, Shernaz Walton, Nick J. Reynolds, Alexa R. Shipman, Christina Ye, Olivia Hughes, Richard B. Warren, Richard Weller, Girish Kumar Gupta, Vera Zietemann
Ireny Iskandar, Richard B. Warren, Zenas Z N Yiu, Jnwn Barker, David Burden, A.D. Ormerod, Nick J. Reynolds, Catherine Smith, Christopher Em Griffiths, Darren M. Ashcroft
K.J. Mason, Juliet N. Barker, Kay Hogan Smith, Philip Hampton, Mark Lunt, Kathleen McElhone, Richard Warren, Zenas Z N Yiu, Christopher Em Griffiths, A. David Burden
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.